Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the Observations

▴ Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny
Aurobindo Pharma reassured stakeholders that it would address these observations within the stipulated time frame.

Aurobindo Pharma, a leading pharmaceutical company, recently announced that it received seven observations from the United States Food and Drug Administration (US FDA) for its unit-II formulation manufacturing facility located in Bhiwadi, Rajasthan. The FDA conducted an inspection of the facility from April 25 to May 3, 2024, resulting in the issuance of these observations.

The Bhiwadi facility, operated by Eugia Pharma Specialities Ltd, a wholly-owned subsidiary of Aurobindo Pharma, underwent scrutiny by the US FDA. According to the company's exchange filing, the observations from the FDA are procedural in nature. Aurobindo Pharma reassured stakeholders that it would address these observations within the stipulated time frame.

This development follows a recent inspection of Aurobindo Pharma's newly-operational injectable facility in Andhra Pradesh, where the US FDA issued three observations. Despite these regulatory challenges, Aurobindo Pharma remains committed to upholding quality standards and ensuring compliance with regulatory requirements.

On the stock market front, shares of Aurobindo Pharma experienced a slight decline of 0.8% on Friday, May 3. However, the company's stock has shown positive performance, with a 6.19% increase in 2024 so far and an impressive 87.27% growth over the past year.

While regulatory inspections and observations are routine in the pharmaceutical industry, Aurobindo Pharma's proactive approach in addressing these issues reflects its commitment to maintaining quality standards and fostering trust among stakeholders. As the company continues to navigate regulatory processes, investors can expect Aurobindo Pharma to prioritize transparency and compliance to ensure the safety and efficacy of its products.

Tags : #

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026